リアルワールドエビデンスソリューション市場レポート：2030年までの動向、予測、競合分析

リアルワールドエビデンス（RWE）ソリューションの動向と予測

世界のリアルワールドエビデンスソリューション市場の将来は、ヘルスケア企業、ヘルスケア支払者、ヘルスケア提供者市場における機会で有望視されています。世界のリアルワールドエビデンスソリューション市場は、2024年から2030年にかけてCAGR 8.1％で成長すると予測されます。この市場の主な促進要因は、リアルワールドエビデンス（RWE）能力の向上に対するバイオサイエンス業界のニーズの高まり、慢性疾患やがんの発生率の上昇、実用的なエビデンスソリューションのための最先端技術の使用の増加です。

• Lucintelは、用途別では、予測期間中、医薬品開発・承認が最大のセグメントであり続けると予測しています。
• エンドユース別では、医薬品承認手続きにおけるリアルワールドエビデンス研究の重要性が高まっていることから、ヘルスケア企業が最大セグメントであり続けると思われます。
• 地域別では、リアルワールドエビデンスサービスプロバイダーの数が増加していることと、政府の規制が良好であることから、予測期間中も北米が最大地域であり続けるでしょう。

リアルワールドエビデンスソリューション市場の戦略的成長機会

RWEソリューション市場は、主要なアプリケーションにおいていくつかの戦略的成長機会を提示しています。これらの機会を活用することで、意思決定を強化し、ヘルスケアの成果を向上させることができます。

• 患者中心のソリューションの強化：患者中心のソリューションの強化は大きな成長機会です。これには、患者が報告する転帰や経験の収集と分析に重点を置いたツールやプラットフォームの構築が含まれます。これらのソリューションは、治療効果や患者満足度に関する貴重な洞察を提供し、個別化ケアの改善を促進します。
• 高度分析プラットフォーム：ビッグデータ、AI、機械学習を活用した高度な分析プラットフォームを拡大する機会があります。これらのプラットフォームは、より高度なデータ分析と予測機能を提供し、ヘルスケア利害関係者が実世界のデータから実用的な洞察を導き出し、十分な情報に基づいた意思決定を行うことを可能にします。
• 統合データエコシステム：統合データエコシステムの構築は、電子カルテ、請求データ、ウェアラブルデバイスなど、さまざまなソースからのデータを組み合わせることで成長機会をもたらします。この統合により、RWEの包括性と精度が向上し、より良い意思決定と政策立案をサポートします。
• 規制コンサルティングサービス：RWEに焦点を当てた規制コンサルティング・サービスの提供は、成長の可能性を秘めています。規制機関が意思決定に実世界のデータを取り入れることが増えるにつれ、規制要件をナビゲートし、コンプライアンスを確保するための専門知識が必要とされています。コンサルティングサービスは、組織が規制当局への申請や承認にRWEを効果的に活用するのに役立ちます。
• データ共有のためのコラボレーションプラットフォーム：ヘルスケアプロバイダー、研究者、テクノロジー企業間のデータ共有のためのコラボレーションプラットフォームの開発は、戦略的な機会です。これらのプラットフォームは、実世界データの交換を促進し、共同研究イニシアチブを促進し、革新的なRWEソリューションの開発を強化します。

RWEソリューション市場における戦略的成長機会には、患者中心のソリューション強化、高度分析プラットフォーム、統合データエコシステム、規制コンサルティングサービス、データ共有のためのコラボレーションプラットフォームなどが含まれます。これらの機会は、RWEソリューションの開発と適用をサポートし、市場の拡大とヘルスケアの意思決定の改善を促進します。

リアルワールドエビデンスソリューション市場促進要因・課題

リアルワールドエビデンス（RWE）ソリューション市場は、技術進歩、経済要因、規制上の考慮事項など、さまざまな市場促進要因・課題の影響を受けます。これらの要素は市場力学を形成し、RWEソリューションの開拓と採用に影響を与えます。

RWEソリューション市場の促進要因には、以下のようなものがあります：

• 技術の進歩：ビッグデータ解析、機械学習、人工知能などの技術開発の速いペースは、大量の実世界データを分析する能力を高める。これらのツールは、より正確な解釈を可能にし、より良い意思決定と個別化治療につながる洞察を提供します。技術の進歩に伴い、異なるデータソースを統合して一緒に分析することも可能になり、RWEソリューションがより強固なものになります。
• 規制当局のサポートとフレームワーク：実世界のエビデンスを意思決定プロセスに含める必要があるという規制当局の受け入れの拡大は、その推進力となっています。例えば、FDAとEMAは、医薬品承認と市場評価にRWEを統合することを目的としたガイドラインを発表しました。このような規制当局のお墨付きは、RWEに法的な裏付けを与え、規制当局への申請や市販後評価での使用を促し、よりエビデンスに基づいたヘルスケアへと向かわせる。
• 個別化医療への需要の高まり：個別化医療に対する需要の高まりは、RWEの必要性を高めています。多様な集団で治療がどのように行われるかを明らかにすることで、この情報は個別化された治療計画の形成を可能にします。このようなオーダーメイド医療への需要が、RWEソリューションへの投資を後押ししています。
• データ利用可能性の向上：電子カルテ（EHR）、ウェアラブルデバイス、その他のデジタルヘルス技術の普及により、実世界データの利用可能性は著しく高まっています。利用可能なデータが増えることで、患者の転帰、治療効果、ヘルスケア利用率などの問題を包括的に分析することが可能になります。アクセス性が向上すれば、ヘルスケアの改善を促す実用的な洞察が生まれ、有用性が高まる。
• 価値に基づくヘルスケアへの注力：価値ベースのヘルスケアモデルは、量よりもアウトカムと費用対効果を重視します。このシフトは、現実世界の設定における治療効果、患者アウトカム、コスト効率に関する情報を提供するRWEによってサポートされています。価値ベースのケアへのこの焦点は、介入の価値を証明し、償還決定を促進するためのツールとしてRWEの採用と一致しています。

RWEソリューション市場における課題は以下の通り：

• データの質と標準化：データの品質と標準化：データの品質と標準化は、RWEにおける主な課題の1つです。データ形式のばらつき、不完全な記録、多様なデータ収集方法は、RWEの信頼性を低下させる可能性があります。これらの問題に対処するためには、標準化されたプロトコルを開発し、精度と使いやすさを向上させるために完全なデータ収集を保証する必要があります。
• プライバシーとセキュリティに関する懸念：患者のプライバシーの保護とデータの安全性の確保は重要な課題です。このような機密性の高い資料の利用が増えることで、個人健康情報が漏洩することへの懸念が広がっています。患者情報を保護し、RWEソリューションへの信頼を維持するためには、規制要件と強固なセキュリティ対策が必要です。
• 多様なデータソースの統合：EHR、患者登録、ウェアラブルデバイスなど、さまざまなデータタイプを組み合わせることで、これらの情報の統合に関連する課題が生じます。

RWEソリューション市場は、技術の進歩、データ主導の洞察に対する需要の高まり、規制当局の支援、データインフラへの投資、協力関係によって牽引されます。しかし、規制上の懸念、データ品質、高い技術コストに関する課題は、市場力学に影響を与えます。RWEソリューションを発展させ、ヘルスケアの意思決定への影響を強化するためには、これらの促進要因と課題のバランスをとることが不可欠です。

目次

第1章 エグゼクティブサマリー

第2章 世界のリアルワールドエビデンスソリューション市場：市場力学

• イントロダクション、背景、分類
• サプライチェーン
• 業界の促進要因と課題

第3章 2018年から2030年までの市場動向と予測分析

• マクロ経済動向（2018～2023年）と予測（2024～2030年）
• 世界のリアルワールドエビデンスソリューション市場の動向（2018～2023年）と予測（2024～2030年）
• 世界のリアルワールドエビデンスソリューション市場：コンポーネント別
  • サービス
  • データセット
• 世界のリアルワールドエビデンスソリューション市場：用途別
  • 医薬品の開発と承認
  • 医療機器の開発と承認
  • 償還/補償および規制上の意思決定
  • 市販後安全性および有害事象モニタリング
• 世界のリアルワールドエビデンスソリューション市場：最終用途別
  • ヘルスケア企業
  • ヘルスケア支払者
  • ヘルスケア提供者
  • その他

第4章 2018年から2030年までの地域別市場動向と予測分析

• 地域別リアルワールドエビデンスソリューション市場
• 北米のリアルワールドエビデンスソリューション市場
• 欧州のリアルワールドエビデンスソリューション市場
• アジア太平洋地域のリアルワールドエビデンスソリューション市場
• その他地域のリアルワールドエビデンスソリューション市場

第5章 競合分析

• 製品ポートフォリオ分析
• 運用統合
• ポーターのファイブフォース分析

第6章 成長機会と戦略分析

• 成長機会分析
  • コンポーネント別の世界のリアルワールドエビデンスソリューション市場の成長機会
  • 用途別の世界のリアルワールドエビデンスソリューション市場の成長機会
  • 最終用途別世界リアルワールドエビデンスソリューション市場の成長機会
  • 地域別の世界のリアルワールドエビデンスソリューション市場の成長機会
• 世界のリアルワールドエビデンスソリューション市場の新たな動向
• 戦略分析
  • 新製品開発
  • 世界のリアルワールドエビデンスソリューション市場のキャパシティ拡大
  • 世界のリアルワールドエビデンスソリューション市場における合併、買収、合弁事業
  • 認証とライセンシング

第7章 主要企業の企業プロファイル

• IQVIA
• IBM
• PPD
• Parexel
• PerkinElmer
• Icon Plc
• Oracle
• Syneos Health
• Cegedim Health Data
• Medpace

Real-World Evidence Solution Trends and Forecast

The future of the global real-world evidence solution market looks promising with opportunities in the healthcare companies, healthcare payers, and healthcare providers markets. The global real-world evidence solution market is expected to grow with a CAGR of 8.1% from 2024 to 2030. The major drivers for this market are the growing industry need in the biosciences for improved Real-World Evidence (RWE) capabilities, the rise in the occurrence of chronic illnesses and cancer, and an increase in the use of cutting-edge technology for practical evidentiary solutions.

• Lucintel forecasts that within the application category, drug development & approval will remain the largest segment over the forecast period.
• Within the end-use category, healthcare companies will remain the largest segment due to the increasing significance of real-world evidence studies in the drug approval procedure.
• In terms of regions, North America will remain the largest region over the forecast period due to the increasing count of real-world evidence service providers and favorable government regulations.

Gain valuable insights for your business decisions with our comprehensive 150+ page report.

Emerging Trends in the Real-World Evidence Solution Market

The Real-World Evidence (RWE) Solution market is influenced by several emerging trends that reflect technological advancements and evolving healthcare needs. These trends are reshaping how real-world data is used to inform healthcare decisions.

• Artificial Intelligence and Machine Learning Integration: RWE analytics can be implemented with AI and ML technologies, which draw on vast health data to perform more efficiently. This improves prediction models by adding more precise parameters to the input of those models.
• Expansion of Data Sources: The range of RWE data sources is widening beyond traditional EHRs and claims to include new sources such as wearable devices, mobile health apps, and social media. This expansion allows for a more in-depth analysis of treatment outcomes and patient experiences in real life.
• Increased Emphasis on Patient-Centric Data: RWE solutions increasingly emphasize the use of patient-reported outcomes (PROs) or patient-centered endpoints (PCEs). PROs capture information from patients through surveys or wearable devices, providing insights into their preferences, quality of life, and treatment impact. This is making medicine more individualized and patient-centered.
• Regulatory Integration and Acceptance: Regulatory agencies have started including RWE in their decision-making systems, acknowledging its role in assessing drug safety, efficacy, and market access. This progress has led to faster approval processes and greater acceptance of RWE for regulatory purposes, often resulting in shorter timelines for new treatments to reach the market and better compliance with regulations.
• Focus on Data Security and Privacy: As the use of real-world data expands, there is a greater focus on ensuring its security. Improved algorithms to secure health data are essential, especially with regulations like GDPR and HIPAA, which require anonymization or encryption techniques. This helps foster trust in RWE solutions while upholding ethical standards in patient information management.

These emerging trends are reshaping the RWE Solution market by advancing data analysis capabilities, focusing on patient-centric approaches, expanding data sources, and increasing regulatory acceptance. The growth of collaborative ecosystems further supports the development and application of RWE solutions, driving innovation and improving decision-making in healthcare.

Recent Developments in the Real-World Evidence Solution Market

Recent developments in the RWE Solution market highlight advancements in technology, data integration, and regulatory practices. These developments are enhancing the effectiveness and scope of RWE solutions, impacting various aspects of healthcare.

• Integration of Advanced Analytics and Machine Learning: Integrating advanced analytics and machine learning with RWE solutions has significantly improved the ability to draw relevant inferences from large amounts of data. Machine learning algorithms can now detect complex patterns, predict patient outcomes, and identify trends that were previously hard to notice. Through this technology, personalized treatment plans are developed, providing more precise predictions and risk assessments, thereby improving decision-making. These advancements facilitate a deeper understanding of how treatments perform in various populations beyond controlled clinical trial settings.
• Enhanced Data Sources and Connectivity: Recent advances have broadened the types of data sources integrated into RWE solutions. Health systems, electronic health records (EHRs), wearable devices, and patient-reported outcomes now blend better together. This broader connectivity helps us understand patients' overall health status and the effects of treatment. By merging different data sets, healthcare providers get a more comprehensive picture of patients' experiences and treatment efficacy, supporting better-informed healthcare decisions for improved care.
• Regulatory Frameworks and Standardization: Progress is being made in developing regulatory frameworks and standards for RWE. Guidelines from organizations such as the FDA and EMA now include the use of real-world data during regulatory submissions. Quality control mechanisms are necessary for maintaining high standards in the development of regulatory practices using RWE, which enforces quality assessment procedures aimed at achieving reliable results. These standards enable harmonized practices for gathering information from patients worldwide, thus providing more credibility for conclusions drawn from RWE accepted by authorities when deciding on inclusion criteria.
• Patient-Centric Approaches and Engagement: Recently, there has been a focus on the direct involvement of patients in generating RWE. Patient-centric approaches, such as patient-reported outcomes (PRO) measures or actively engaging patients during data collection, are becoming more popular. This shows recognition of the importance of patients' own stories about their treatments. By considering patient feedback and preferences, health solutions can be customized to meet different needs, leading to more improved and personalized care strategies.
• Expansion of Real-World Evidence in Comparative Effectiveness Research: The use of RWE in comparative effectiveness research has increased to compare how well treatments work in usual clinical practice or other healthcare settings. RWE looks at how various therapies affect diverse patient populations and environments, which is critical for understanding actual outcomes. The expansion of RWE in this field helps identify the most effective treatments, optimize healthcare delivery, and support evidence-based clinical decision-making.

Recent developments in the RWE Solution market, including advancements in analytics, data integration, regulatory support, patient-centric data collection, and collaborative partnerships, are enhancing the effectiveness and scope of real-world evidence. These developments contribute to more informed decision-making and improved patient outcomes across healthcare systems.

Strategic Growth Opportunities for Real-World Evidence Solution Market

The RWE Solution market presents several strategic growth opportunities across key applications. Leveraging these opportunities can enhance decision-making and improve healthcare outcomes.

• Enhanced Patient-Centric Solutions: Developing enhanced patient-centric solutions represents a significant growth opportunity. This involves creating tools and platforms that focus on collecting and analyzing patient-reported outcomes and experiences. These solutions provide valuable insights into treatment effectiveness and patient satisfaction, driving improvements in personalized care.
• Advanced Analytics Platforms: There is an opportunity to expand advanced analytics platforms that leverage big data, AI, and machine learning. These platforms can offer more sophisticated data analysis and predictive capabilities, enabling healthcare stakeholders to derive actionable insights from real-world data and make informed decisions.
• Integrated Data Ecosystems: Building integrated data ecosystems presents a growth opportunity by combining data from various sources, including electronic health records, claims data, and wearable devices. This integration enhances the comprehensiveness and accuracy of RWE, supporting better decision-making and policy development.
• Regulatory Consulting Services: Providing regulatory consulting services focused on RWE offers growth potential. As regulatory agencies increasingly incorporate real-world data into decision-making, there is a need for expertise in navigating regulatory requirements and ensuring compliance. Consulting services can help organizations leverage RWE effectively for regulatory submissions and approvals.
• Collaboration Platforms for Data Sharing: Developing collaboration platforms for data sharing among healthcare providers, researchers, and technology companies is a strategic opportunity. These platforms facilitate the exchange of real-world data, promote joint research initiatives, and enhance the development of innovative RWE solutions.

Strategic growth opportunities in the RWE Solution market include enhanced patient-centric solutions, advanced analytics platforms, integrated data ecosystems, regulatory consulting services, and collaboration platforms for data sharing. These opportunities support the development and application of RWE solutions, driving market expansion and improving healthcare decision-making.

Real-World Evidence Solution Market Driver and Challenges

The Real-World Evidence (RWE) Solution market is influenced by various drivers and challenges, including technological advancements, economic factors, and regulatory considerations. These elements shape market dynamics and impact the development and adoption of RWE solutions.

The factors responsible for driving the RWE solution market include:

• Technological Advancements: The fast pace of technological development, such as big data analytics, machine learning, and artificial intelligence, increases the ability to analyze large amounts of real-world data. These tools enable more accurate interpretations and offer insights that lead to better decision-making and personalized treatments. As technology advances, it also helps integrate different data sources and analyze them together, making RWE solutions more robust.
• Regulatory Support and Frameworks: Growing acceptance by regulatory agencies that real-world evidence must be included in decision-making processes has been a driving force. For example, the FDA and EMA have issued guidelines aimed at integrating RWE into drug approvals and market assessments. Such regulatory endorsements provide RWE with legal backing, encouraging its use in regulatory submissions and post-marketing evaluations, thus moving towards more evidence-based healthcare.
• Growing Demand for Personalized Medicine: The increasing demand for personalized medicine fuels the need for RWE. By revealing how treatments perform across diverse populations, this information allows for the formation of personalized treatment plans. This demand for customized care drives investments in RWE solutions.
• Increased Data Availability: The availability of real-world data has risen significantly due to the proliferation of electronic health records (EHRs), wearable devices, and other digital health technologies. More available data makes it possible to comprehensively analyze issues such as patient outcomes, treatment effectiveness, and healthcare utilization rates. Better accessibility enhances its usefulness by creating actionable insights that drive improvements in healthcare.
• Focus on Value-Based Healthcare: Value-based healthcare models emphasize outcomes and cost-effectiveness over volume. This shift is supported by RWE, which provides information about treatment effectiveness, patient outcomes, and cost efficiency in real-world settings. This focus on value-based care aligns with the adoption of RWE as a tool to prove the worthiness of interventions and facilitate reimbursement decisions.

Challenges in the RWE solution market include:

• Data Quality and Standardization: Ensuring data quality and standardization has been one of the main challenges in RWE. Variations in data formats, incomplete records, and diverse methods of data collection may make RWE less reliable. To address these issues, it is necessary to develop standardized protocols and ensure complete data collection for improved accuracy and usability.
• Privacy and Security Concerns: Protecting patient privacy and ensuring data security are critical challenges. Concerns about personal health information being disclosed due to more usage of such sensitive materials are prevalent. Regulatory requirements and robust security measures are necessary to safeguard patient information and maintain trust in RWE solutions.
• Integration of Diverse Data Sources: Combining various data types, such as EHRs, patient registries, and wearable devices, presents integration challenges associated with merging this information.

The RWE Solution market is driven by technological advancements, increased demand for data-driven insights, regulatory support, investment in data infrastructure, and collaborations. However, challenges related to regulatory concerns, data quality, and high technology costs impact market dynamics. Balancing these drivers and challenges is essential for advancing RWE solutions and enhancing their impact on healthcare decision-making.

List of Real-World Evidence Solution Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies real-world evidence solution companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the real-world evidence solution companies profiled in this report include-

• IQVIA
• IBM
• PPD
• Parexel
• PerkinElmer
• Icon Plc
• Oracle
• Syneos Health
• Cegedim Health Data
• Medpace

Real-World Evidence Solution by Segment

The study includes a forecast for the global real-world evidence solution by component, application, end use, and region.

Real-World Evidence Solution Market by Component [Analysis by Value from 2018 to 2030]:

• Services
• Data Sets

Real-World Evidence Solution Market by Application [Analysis by Value from 2018 to 2030]:

• Drug Development & Approvals
• Medical Device Development & Approvals
• Reimbursement/Coverage & Regulatory Decision Making
• Post Market Safety & Adverse Events Monitoring

Real-World Evidence Solution Market by End Use [Analysis by Value from 2018 to 2030]:

• Healthcare Companies
• Healthcare Payers
• Healthcare Providers
• Others

Real-World Evidence Solution Market by Region [Shipment Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Real-World Evidence Solution Market

The Real-World Evidence (RWE) Solution market is evolving rapidly as healthcare stakeholders increasingly seek insights from real-world data to improve decision-making and patient outcomes. Advances in technology, data analytics, and regulatory changes are driving the development of RWE solutions, influencing various regions differently. Here's a look at recent developments in key markets: the United States, China, Germany, and India.

• United States: RWE solutions in the US have evolved to incorporate advanced analytics and artificial intelligence (AI), leading to better data insights. The FDA has increasingly embraced RWE in regulatory decisions, paving the way for the use of EHRs and claims data for drug approvals as well as post-market surveillance. Additionally, many tech companies are partnering with health facilities to enhance interoperability among different healthcare systems and improve patient outcomes. Investments in cloud computing and machine learning have further strengthened the functionality of RWE, enabling organizations to obtain more accurate results.
• China: China's RWE solutions have made significant advances due to rapidly growing data collection and analysis technologies. The government is expected to rely more on RWE in its drug approval processes and healthcare policy development, particularly through projects such as the 13th Five-Year Plan on Drug Safety. Investments in big data analytics and AI technology have increased the capacity to analyze large volumes of EHRs and patient registries. Initiatives include increased collaboration between Chinese tech companies and healthcare institutions, leading to better data integration. Furthermore, regulatory bodies in China are increasingly embracing RWE in their decision-making processes.
• Germany: Data protection laws, along with the country's emphasis on advanced analytics, have enabled Germany to make significant strides toward RWE solutions. The robustness of Germany's e-health databases, combined with a strong focus on privacy, facilitates these applications by ensuring strict adherence to regulations concerning the storage, sharing, and dissemination of personal medical information. Recent developments include the use of AI and machine learning to analyze patient records and optimize clinical trial designs. Additionally, national initiatives promoting RWD for evidence-based healthcare decisions and policies have enhanced Germany's capacity for health research.
• India: In India, RWE solutions are advancing through increased investments in digital healthcare infrastructure and data analytics. Initiatives such as the National Digital Health Mission aim to promote the use of RWE for health reforms and improved patient care. With better data collection through EHRs and health information systems, there is a greater ability to track public health trends. Additionally, many local tech start-ups are collaborating with international pharmaceutical companies to accelerate the deployment of RWE in drug discovery and healthcare policy-making.

Features of the Global Real-World Evidence Solution Market

Market Size Estimates: Real-world evidence solution market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Real-world evidence solution market size by component, application, end use, and region in terms of value ($B).

Regional Analysis: Real-world evidence solution market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different component, application, end use, and regions for the real-world evidence solution market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the real-world evidence solution market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this market or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the real-world evidence solution market by component (services and data sets), application (drug development & approvals, medical device development & approvals, reimbursement/coverage & regulatory decision making, and post market safety & adverse events monitoring), end use (healthcare companies, healthcare payers, healthcare providers, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Real-World Evidence Solution Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

• 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
• 3.2. Global Real-World Evidence Solution Market Trends (2018-2023) and Forecast (2024-2030)
• 3.3: Global Real-World Evidence Solution Market by Component
  • 3.3.1: Services
  • 3.3.2: Data Sets
• 3.4: Global Real-World Evidence Solution Market by Application
  • 3.4.1: Drug Development & Approvals
  • 3.4.2: Medical Device Development & Approvals
  • 3.4.3: Reimbursement/Coverage & Regulatory Decision Making
  • 3.4.4: Post Market Safety & Adverse Events Monitoring
• 3.5: Global Real-World Evidence Solution Market by End Use
  • 3.5.1: Healthcare Companies
  • 3.5.2: Healthcare Payers
  • 3.5.3: Healthcare Providers
  • 3.5.4: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

• 4.1: Global Real-World Evidence Solution Market by Region
• 4.2: North American Real-World Evidence Solution Market
  • 4.2.1: North American Market by Application: Drug Development & Approvals, Medical Device Development & Approvals, Reimbursement/Coverage & Regulatory Decision Making, and Post Market Safety & Adverse Events Monitoring
  • 4.2.2: North American Market by End Use: Healthcare Companies, Healthcare Payers, Healthcare Providers, and Others
• 4.3: European Real-World Evidence Solution Market
  • 4.3.1: European Market by Application: Drug Development & Approvals, Medical Device Development & Approvals, Reimbursement/Coverage & Regulatory Decision Making, and Post Market Safety & Adverse Events Monitoring
  • 4.3.2: European Market by End Use: Healthcare Companies, Healthcare Payers, Healthcare Providers, and Others
• 4.4: APAC Real-World Evidence Solution Market
  • 4.4.1: APAC Market by Application: Drug Development & Approvals, Medical Device Development & Approvals, Reimbursement/Coverage & Regulatory Decision Making, and Post Market Safety & Adverse Events Monitoring
  • 4.4.2: APAC Market by End Use: Healthcare Companies, Healthcare Payers, Healthcare Providers, and Others
• 4.5: ROW Real-World Evidence Solution Market
  • 4.5.1: ROW Market by Application: Drug Development & Approvals, Medical Device Development & Approvals, Reimbursement/Coverage & Regulatory Decision Making, and Post Market Safety & Adverse Events Monitoring
  • 4.5.2: ROW Market by End Use: Healthcare Companies, Healthcare Payers, Healthcare Providers, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Real-World Evidence Solution Market by Component
  • 6.1.2: Growth Opportunities for the Global Real-World Evidence Solution Market by Application
  • 6.1.3: Growth Opportunities for the Global Real-World Evidence Solution Market by End Use
  • 6.1.4: Growth Opportunities for the Global Real-World Evidence Solution Market by Region
• 6.2: Emerging Trends in the Global Real-World Evidence Solution Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Real-World Evidence Solution Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Real-World Evidence Solution Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: IQVIA
• 7.2: IBM
• 7.3: PPD
• 7.4: Parexel
• 7.5: PerkinElmer
• 7.6: Icon Plc
• 7.7: Oracle
• 7.8: Syneos Health
• 7.9: Cegedim Health Data
• 7.10: Medpace